Sinapultide CAS NO.138531-07-4

Sinapultide (CAS 138531-07-4) is a synthetic, amphipathic peptide designed to mimic the function of pulmonary surfactant protein B (SP-B). This cGMP-manufactured peptide consists of 25 amino acids and is engineered to reduce surface tension at the air-liquid interface of the alveoli. It is primarily utilized in critical care formulations to improve lung compliance and oxygenation, playing a crucial role in the manag…

SupplierGlobal Technology Co., Ltd.www.hqtechtirz.com

Send product inquiry View on supplier website More from this supplier

Source categories

Peptides

About this product

Product information from the supplier.

TECHNICAL SPECIFICATIONS

Item	Specification
Product Name	Sinapultide
CAS NO.	138531-07-4
Appearance	White to off-white lyophilized powder
Molecular Formula	C126H238N26022
Molecular Weight	2469.41 g/mol
Purity (RP-HPLC)	≥ 98.0%
Solubility	Soluble in water, dilute saline, and aqueous buffers; sparingly soluble in organic solvents
Endotoxin	< 1.0 EU/mg
Biological Activity	≥90% relative potency (measured by surfactant activity and lipid bilayer interaction assays)
Storage Conditions	Store at -20°C to -80°C in a dry, dark environment; avoid repeated freeze-thaw cycles.
Stock Location	Stock in USA
MOQ	1g

1.MECHANISM OF ACTION

Sinapultide mimics the action of endogenous surfactant protein B by inserting into the phospholipid monolayer at the alveolar surface. Its amphipathic structure allows it to facilitate the adsorption and spreading of phospholipids, stabilize the surfactant film during expiration, and prevent alveolar collapse (atelectasis). This action dramatically lowers surface tension, increases lung compliance, and improves gas exchange efficiency.

2.PRODUCT INDICATIONS

Neonatal Respiratory Distress Syndrome (RDS): For the prevention and treatment of RDS in premature infants.

Acute Respiratory Distress Syndrome (ARDS): As a therapeutic agent for improving oxygenation in adult patients with ARDS.

Surfactant Replacement Therapy: As a key active component in synthetic surfactant preparations.

3.CLINICAL EFFICACY OF PRODUCT

Clinical studies demonstrate that synthetic surfactant preparations containing Sinapultide significantly improve oxygenation (PaO2/FiO2 ratio), reduce the need for high ventilator pressures, and decrease the incidence of complications such as pneumothorax in premature infants with RDS. In adult ARDS, it has shown potential to improve lung compliance and gas exchange, contributing to reduced mortality and shorter duration of mechanical ventilation.

4.DELIVERY & SHIPPING

We specialize in global logistics for various cosmetic peptides. Your order will be handled with the utmost care, ensuring safe, reliable, and intact delivery.
Professional and Secure Packaging
Each bottle of peptide is protected with a special packaging solution to ensure stability and integrity during transportation.
We can also customize packaging according to customer needs.
Shipping Methods
Main Method: International Air Freight

We primarily use DHL, FedEx, UPS, and TNT because of their global reliability, speed, and advanced tracking systems. Air freight ensures the fastest transit time and minimizes the impact of environmental factors on the product.